(Q39463449)

12 September 2017

1 reference

title

Somatostatin and cancer (English)

1 reference

12 September 2017

Robbins RJ

1

1 reference

12 September 2017

1 August 1996

1 reference

12 September 2017

1 reference

12 September 2017

45

1 reference

12 September 2017

8 Suppl 1

1 reference

12 September 2017

98-100

1 reference

Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Somatostatin can locally inhibit proliferation and differentiation of cartilage and bone precursor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Somatostatin (SSTR2) receptors mediate phospholipase C-independent Ca2+ mobilization in rat AR42J pancreas cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Regulation of phosphoprotein phosphatase by somatostatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Multiple actions of somatostatin in neoplastic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Role of tumor-derived fibroblasts in the growth of primary cultures of human breast-cancer cells: effects of epidermal growth factor and the somatostatin analogue octreotide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Somatostatin-receptor scintigraphy in primary breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

The value of octreotide scintigraphy in patients with lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Somatostatin-receptor imaging in the localization of endocrine tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

111Indium (DTPA-octreotide) scintigraphy in patients with cerebral gliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Therapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Octreotide reduces the kinetic index, proliferating cell nuclear antigen-maximum proliferative index, in patients with colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2896%2990096-7

10.1016/S0026-0495(96)90096-7

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference

PubMed ID

8769396